Testicular Cancer - Global Pipeline Insights, 2022: With Analysis of Cabazitaxel, SGN-ALPV, BNT211, Claudin 6 Program, SGN-ALPV & LEAD 472

17 Jan 2023
www.prnewswire.com
Phase 2Drug ApprovalImmunotherapy
DUBLIN, Jan. 17, 2023 /PRNewswire/ -- The "Testicular Cancer - Pipeline Insights, 2022" clinical trials has been added to
ResearchAndMarkets.com's offering.
This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Testicular Cancer Understanding
Testicular cancer is one of the most common malignancies in men aged 15 to 45 years. Etiology is multifactorial, comprising various genetic and environmental factors. With advancements in knowledge about the epidemiology, pathophysiology, and evaluation modalities, advanced management options are now available. With cure rates as high as 90% and >95% 5-year survival rate, testicular cancer is one of the most curable malignancies.
With effective management, the prognosis is excellent with >90% cure rate and >95% five-year survival rate. Complex environmental and genetic factors are involved in the development of testicular cancer; common risk factors include cryptorchidism, family history of testicular cancer, personal history of testicular cancer in the contralateral testis, age, and ethnicity. Initial evaluation includes history and physical examination, tumor marker assessment, and scrotal ultrasound. Once a solid intratesticular tumor is identified, radical inguinal orchiectomy is performed both for diagnostic and therapeutic purposes. Tumor staging guides further management with options including active surveillance, chemotherapy, retroperitoneal lymph node dissection, and radiation therapy.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Testicular Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Testicular Cancer.
In June 2022, BioNTech SE announced that that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to BioNTech's fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors. BNT211 is a potential first-in-class therapeutic approach which comprises a synergistic combination of two of the Company's proprietary drug products, an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).
Testicular Cancer Emerging Drugs Chapters
This segment of the Testicular Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010. Cabazitaxel is a microtubule inhibitor.
Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell. It is currently being investigated in Phase II clinical trial to treat patients with Testicular cancer.
Testicular Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Testicular Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Testicular Cancer
There are approx. 5+ key companies which are developing the therapies for Testicular Cancer. The companies which have their Testicular Cancer drug candidates in the most advanced stage, i.e. Phase II include, Sanofi.
Testicular Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical.
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Testicular Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Testicular Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Testicular Cancer drugs.
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Testicular Cancer drugs?
How many Testicular Cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Testicular Cancer?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Testicular Cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Testicular Cancer and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Leadartis
Key Products
SGN-ALPV
Claudin 6 Program
SGN-ALPV
LEAD 472
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/2o8iqm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.